Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.77

(-0.56%)

Long Term Debt Summary of Vivoryon Therapeutics N.V.

  • Vivoryon Therapeutics N.V.'s latest annual long term debt in 2023 was - EUR , down -100.0% from previous year.
  • Vivoryon Therapeutics N.V.'s latest quarterly long term debt in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported annual long term debt of 38 Thousand EUR in 2022, down -71.21% from previous year.
  • Vivoryon Therapeutics N.V. reported annual long term debt of 132 Thousand EUR in 2021, down -41.07% from previous year.
  • Vivoryon Therapeutics N.V. reported quarterly long term debt of - EUR for 2023 Q4, down 0.0% from previous quarter.
  • Vivoryon Therapeutics N.V. reported quarterly long term debt of 10 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Vivoryon Therapeutics N.V. (2023 - 2010)

Historical Annual Long Term Debt of Vivoryon Therapeutics N.V. (2023 - 2010)

Year Long Term Debt Long Term Debt Growth
2023 - EUR -100.0%
2022 38 Thousand EUR -71.21%
2021 132 Thousand EUR -41.07%
2020 224 Thousand EUR -28.89%
2019 315 Thousand EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR 0.0%
2013 - EUR 0.0%
2012 - EUR 0.0%
2011 - EUR 0.0%
2010 - EUR 0.0%

Peer Long Term Debt Comparison of Vivoryon Therapeutics N.V.

Name Long Term Debt Long Term Debt Difference
Boiron SA 6.64 Million EUR 100.0%
Laboratorios Farmaceuticos Rovi, S.A. 38.57 Million EUR 100.0%
Vetoquinol SA 9.66 Million EUR 100.0%
Valneva SE 132.76 Million EUR 100.0%
AB Science S.A. 16.98 Million EUR 100.0%
Nanobiotix S.A. 41.66 Million EUR 100.0%
PHAXIAM Therapeutics S.A. 7.03 Million EUR 100.0%
BioSenic S.A. 15.57 Million EUR 100.0%
ABIVAX Société Anonyme 44.69 Million EUR 100.0%
Formycon AG 7.81 Million EUR 100.0%